These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33496327)

  • 41. Particulate Shiga Toxin 2 in Blood is Associated to the Development of Hemolytic Uremic Syndrome in Children.
    Brigotti M; He X; Carnicelli D; Arfilli V; Porcellini E; Galassi E; Tazzari PL; Ricci F; Patfield SA; Testa S; Paglialonga F; Picicco D; Caprioli A; Scavia G; Morabito S; Ardissino G
    Thromb Haemost; 2020 Jan; 120(1):107-120. PubMed ID: 31858520
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Involvement of NF-κB1 and the Non-canonical NF-κB Signaling Pathway in the Pathogenesis of Acute Kidney Injury in Shiga-toxin-2-induced Hemolytic-uremic Syndrome in Mice.
    Sobbe IV; Krieg N; Dennhardt S; Coldewey SM
    Shock; 2021 Oct; 56(4):573-581. PubMed ID: 32433206
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Shiga Toxin 2a-Induced Endothelial Injury in Hemolytic Uremic Syndrome: A Metabolomic Analysis.
    Betzen C; Plotnicki K; Fathalizadeh F; Pappan K; Fleming T; Bielaszewska M; Karch H; Tönshoff B; Rafat N
    J Infect Dis; 2016 Mar; 213(6):1031-40. PubMed ID: 26582960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Compensatory renal growth protects mice against Shiga toxin 2-induced toxicity.
    Camerano GV; Bustuoabad OD; Meiss RP; Gómez SA; Fernández GC; Isturiz MA; Palermo MS; Dran GI
    Pediatr Nephrol; 2006 Aug; 21(8):1082-92. PubMed ID: 16703367
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and Evaluation of a Novel VHH-Based Immunocapture Assay for High-Sensitivity Detection of Shiga Toxin Type 2 (Stx2) in Stool Samples.
    Melli LJ; Zylberman V; Hiriart Y; Lauche CE; Baschkier A; Pardo R; Miliwebsky E; Chinen I; Rivas M; Goldbaum FA; Ugalde JE; Comerci DJ; Ciocchini AE
    J Clin Microbiol; 2020 Feb; 58(3):. PubMed ID: 31826960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promoter sequence of Shiga toxin 2 (Stx2) is recognized in vivo, leading to production of biologically active Stx2.
    Bentancor LV; Mejías MP; Pinto A; Bilen MF; Meiss R; Rodriguez-Galán MC; Baez N; Pedrotti LP; Goldstein J; Ghiringhelli PD; Palermo MS
    mBio; 2013 Oct; 4(5):e00501-13. PubMed ID: 24085779
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome.
    Siegler RL; Pysher TJ; Tesh VL; Taylor FB
    J Am Soc Nephrol; 2001 Jul; 12(7):1458-1467. PubMed ID: 11423574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rab7b participation on the TLR4 (Toll-like receptor) endocytic pathway in Shiga toxin-associated Hemolytic Uremic Syndrome (HUS).
    Lafalla Manzano AF; Gil Lorenzo AF; Bocanegra V; Costantino VV; Cacciamani V; Benardon ME; Vallés PG
    Cytokine; 2019 Sep; 121():154732. PubMed ID: 31153054
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bruton's tyrosine kinase inhibition attenuates disease progression by reducing renal immune cell invasion in mice with hemolytic-uremic syndrome.
    Kröller S; Wissuwa B; Dennhardt S; Krieg N; Thiemermann C; Daniel C; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2023; 14():1105181. PubMed ID: 36911665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The oxidative stress induced in vivo by Shiga toxin-2 contributes to the pathogenicity of haemolytic uraemic syndrome.
    Gomez SA; Abrey-Recalde MJ; Panek CA; Ferrarotti NF; Repetto MG; Mejías MP; Fernández GC; Vanzulli S; Isturiz MA; Palermo MS
    Clin Exp Immunol; 2013 Sep; 173(3):463-72. PubMed ID: 23607458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. von Willebrand Factor expression in a Shiga toxin-mediated primate model of hemolytic uremic syndrome.
    Pysher TJ; Siegler RL; Tesh VL; Taylor FB
    Pediatr Dev Pathol; 2002; 5(5):472-9. PubMed ID: 12196894
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous Shiga toxin 2 promotes enteritis and renal injury characterized by polymorphonuclear leukocyte infiltration and thrombosis in Dutch Belted rabbits.
    García A; Marini RP; Catalfamo JL; Knox KA; Schauer DB; Rogers AB; Fox JG
    Microbes Infect; 2008 May; 10(6):650-6. PubMed ID: 18462972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ingested Shiga toxin 2 (Stx2) causes histopathological changes in kidney, spleen, and thymus tissues and mortality in mice.
    Rasooly R; Do PM; Griffey SM; Vilches-Moure JG; Friedman M
    J Agric Food Chem; 2010 Aug; 58(16):9281-6. PubMed ID: 20681531
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tolerance to lipopolysaccharide (LPS) regulates the endotoxin effects on Shiga toxin-2 lethality.
    Alves-Rosa F; Beigier-Bompadre M; Fernández G; Barrionuevo P; Mari L; Palermo M; Isturiz M
    Immunol Lett; 2001 Mar; 76(2):125-31. PubMed ID: 11274731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathogenic functions and diagnostic utility of cytokines/chemokines in EHEC-HUS.
    Shimizu M
    Pediatr Int; 2020 Mar; 62(3):308-315. PubMed ID: 31742829
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Is Shigatoxin 1 protective for the development of Shigatoxin 2-related hemolytic uremic syndrome in children? Data from the ItalKid-HUS Network.
    Ardissino G; Possenti I; Vignati C; Daprai L; Capone V; Brigotti M; Luini MV; Consonni D; Montini G
    Pediatr Nephrol; 2020 Oct; 35(10):1997-2001. PubMed ID: 32734345
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.
    Ikeda M; Ito S; Honda M
    Pediatr Nephrol; 2004 May; 19(5):485-9. PubMed ID: 15007712
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Divergent roles of haptoglobin and hemopexin deficiency for disease progression of Shiga-toxin-induced hemolytic-uremic syndrome in mice.
    Pirschel W; Mestekemper AN; Wissuwa B; Krieg N; Kröller S; Daniel C; Gunzer F; Tolosano E; Bauer M; Amann K; Heinemann SH; Coldewey SM
    Kidney Int; 2022 Jun; 101(6):1171-1185. PubMed ID: 35031328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting the innate repair receptor axis
    Dennhardt S; Pirschel W; Wissuwa B; Imhof D; Daniel C; Kielstein JT; Hennig-Pauka I; Amann K; Gunzer F; Coldewey SM
    Front Immunol; 2022; 13():1010882. PubMed ID: 36211426
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cardiovascular impairment in Shiga-toxin-2-induced experimental hemolytic-uremic syndrome: a pilot study.
    Neu C; Wissuwa B; Thiemermann C; Coldewey SM
    Front Immunol; 2023; 14():1252818. PubMed ID: 37809105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.